Key Insights

Highlights

Success Rate

75% trial completion

Treatment Research

6 treatments under study, led by Transcatheter Aortic Valve Replacement

Research Leaders

5 sponsors active, led by Abbott Medical Devices

Related Conditions

Often studied with 8 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

20.0%

1 terminated out of 5 trials

Success Rate

75.0%

-11.6% vs benchmark

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

133%

4 of 3 completed with results

Key Signals

4 with results75% success

Data Visualizations

Phase Distribution

4Total
Not Applicable (3)
Phase 3 (1)

Trial Status

Completed3
Active Not Recruiting1
Terminated1

Trial Success Rate

75.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (5)

Showing 5 of 5 trials
NCT06510855Not ApplicableActive Not Recruiting

DurAVR™ THV EU-EFS

NCT05171712Not ApplicableCompleted

Portico and Navitor India Clinical Trial

NCT05666713Not ApplicableCompleted

NHLBI Transmural Electrosurgery LeafLet Traversal And Laceration Evaluation (TELLTALE) BASILICA-TAVR Trial

NCT05002088Completed

Portico Valve-in-Valve Retrospective Registry

NCT04142658Phase 3Terminated

PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban

Showing all 5 trials

Research Network

Common Treatments

  • Transcatheter Aortic Valve Replacement2
  • Apixaban1
  • Warfarin1
  • Telltale Basilica Procedure1
  • Onx Aortic Mechanical Valve1

Active Sponsors

  • Abbott Medical Devices2
  • Anteris Technologies Ltd.1
  • Artivion Inc.1
  • Duke Clinical Research Institute1
  • National Heart, Lung, and Blood Institute (NHLBI)1

Top Investigators

Related Conditions

  • Aortic Valve Stenosis3
  • Aortic Stenosis2
  • Aortic Insufficiency2
  • Aortic Valve Disease2
  • Valvular Heart Disease1

Activity Timeline